Resveratrol in Knee Osteoarthritis

Last updated: January 30, 2025
Sponsor: Assistance Publique - Hôpitaux de Paris
Overall Status: Completed

Phase

3

Condition

Osteoarthritis

Knee Injuries

Treatment

oral placebo

oral resveratrol

Clinical Study ID

NCT02905799
P150938
2016-A01310-51
  • Ages > 40
  • All Genders

Study Summary

The purpose of this study is to determine whether resveratrol is effective in the treatment of painful knee osteoarthritis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 40 years-old

  • Knee osteoarthritis fulfilling 1986 American College of Rheumatology (ACR) criteria

  • Pain on numeric rating scale ≥ 40/100

  • Symptom duration ≥ 1 month

  • Kellgren and Lawrence X-Ray score 1, 2 or 3

  • Written consent obtained

  • Health insurance cover

Exclusion

Exclusion Criteria:

  • History of symptomatic crystal or inflammatory arthritis

  • Knee surgery ≤ 1 year

  • Knee trauma ≤ 2 months

  • Knee intra-articular injections of corticosteroids and/or hyaluronic acid ≤ 2 months

  • Neurologic disorders involving the lower limbs

  • Patient not understanding and not speaking french

  • Participation in another biomedical research

  • Contraindication to resveratrol or hypersensitivity to any of its constituents

  • Current use of intramuscular, intravenous or oral corticosteroids

  • Uncontrolled diseases that may require intramuscular, intravenous or oralcorticosteroids

  • Current use of anticoagulants

Study Design

Total Participants: 142
Treatment Group(s): 2
Primary Treatment: oral placebo
Phase: 3
Study Start date:
November 09, 2017
Estimated Completion Date:
May 12, 2022

Study Description

Osteoarthritis (OA) is the first cause of handicap in individuals over 40 years-old in France. OA physiopathology is driven in part by local joint inflammation responsible for pain and joint destruction. Experimental studies have shown that resveratrol, a molecule antagonist to the aryl hydrocarbon receptor, has anti-inflammatory and chondroprotective properties in vitro and in vivo. The investigators hypothesize that oral resveratrol, in a new formulation improving its bioavailability, could reduce knee pain at 3 months as compared with placebo in people with knee OA.

Connect with a study center

  • Rehabilitation department , CHU Clermont-Ferrand

    Cebazat, 63118
    France

    Site Not Available

  • Rehabilitation Department, Cochin Hospital

    Paris, 75014
    France

    Site Not Available

  • Rheumatology Department, Saint Antoine Hospital

    Paris, 75012
    France

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.